Immunotherapy biotech companies focus on using the body’s immune system to fight diseases, particularly cancer. This sector encompasses firms engaged in developing biological drugs, cell therapies, and innovative treatment protocols. These companies are at the forefront of research and aim to meet severe medical needs through cutting-edge solutions. As clinical trials expand and regulatory approvals increase, the industry is poised for rapid growth with the potential to revolutionize how various cancers are treated, providing new hope for patients worldwide. Recent advancements have also seen rising collaboration efforts between firms, enhancing research synergies and accelerating the development of therapies.

The companies listed here vary in size, with many employing between 50 to 5,000 staff members. They are primarily located in the USA, but also have a notable presence in Europe and Asia. Founded between the early 1990s and 2020, these firms specialize in immunotherapy products and related research. Noteworthy names include Kite Pharma, known for CAR T-cell therapies, and Chi-Med, focusing on targeted therapies. Their shared commitment to innovation is driving significant advancements in cancer treatment.

Continue reading to discover the top immunotherapy biotech companies.

Top 26 Immunotherapy Biotech Companies

1. Kite Pharma

• Website: kitepharma.com
• Ownership type: Corporate
• Headquarters: Santa Monica, California, United States (USA)
• Employee distribution: United States (USA) 65%, Netherlands 28%, United Kingdom (UK) 2%, Other 5%
• Latest funding: $11.9B, August 2017
• Founded year: 2009
• Headcount: 1001-5000
• LinkedIn: kite-pharma-inc-

Kite Pharma, Inc. is a biotechnology company based in Santa Monica, California, founded in 2009. The company is dedicated to developing innovative cancer immunotherapy products, particularly focusing on CAR T-cell therapies. Kite Pharma aims to leverage the power of the immune system to treat various blood cancers, providing effective treatment solutions for patients and healthcare providers. The company operates with a strong commitment to research and development, ensuring that advanced therapies are accessible to those in need. Kite Pharma has made notable strides in the industry, particularly with its flagship products, YESCARTA (axicabtagene ciloleucel) and TECARTUS (brexucabtagene autoleucel), which have shown promising results in clinical settings. Their robust pipeline includes ongoing research into new therapies and technologies, further solidifying their position in the immunotherapy space.

2. Dendreon

• Website: dendreon.com
• Ownership type: Corporate
• Headquarters: Seal Beach, California, United States (USA)
• Employee distribution: United States (USA) 97%, Other 3%
• Latest funding: $819.9M, June 2017
• Founded year: 1992
• Headcount: 501-1000
• LinkedIn: dendreon

Dendreon Pharmaceuticals LLC, based in Seal Beach, California, is a biotechnology company focused on immunotherapy for cancer treatment. Founded in 1992, Dendreon specializes in harnessing the power of the immune system to combat cancer, with its flagship product, Provenge (sipuleucel-T), being the first FDA-approved cellular immunotherapy for advanced prostate cancer. This innovative treatment reprograms the patient's immune cells to identify and attack cancer cells, contributing to improved survival rates for patients. Dendreon also provides cellular therapy manufacturing services, supporting the development of new cancer therapies. The company has been involved in various clinical trials to explore the potential of Provenge in different patient populations, demonstrating its commitment to advancing cancer treatment. With approximately 610 employees, Dendreon continues to play a significant role in the biopharmaceutical industry, focusing on research, development, and strategic partnerships to enhance patient care.

3. Seattle Genetics

• Website: seattlegenetics.com
• Ownership type: Private
• Headquarters: Bothell, Washington, United States (USA)
• Founded year: 1998
• Headcount: 1001-5000
• LinkedIn: seattle-genetics

Seattle Genetics, founded in 1998 and based in Bothell, Washington, is a biopharmaceutical company that focuses on developing innovative therapies for cancer treatment. The company is particularly known for its pioneering work in antibody-drug conjugates (ADCs), which combine antibodies with potent cytotoxic drugs to target and kill cancer cells while sparing healthy tissue. Seattle Genetics has established a strong presence in the oncology market, with several approved products and a robust pipeline aimed at addressing various types of cancer. Their research efforts are centered on harnessing the immune system to improve patient outcomes, making them a significant player in the immunotherapy sector. With a workforce of over 2,000 employees, Seattle Genetics continues to push the boundaries of cancer treatment through its commitment to scientific innovation and clinical research.

4. Chi-Med (Hutchison China MediTech)

• Website: chi-med.com
• Ownership type: Private
• Headquarters: Hong Kong S.A.R
• Founded year: 2000
• Headcount: 5001-10000
• LinkedIn: hchimed

Chi-Med (Hutchison China MediTech) is a biopharmaceutical company based in Hong Kong, founded in 2000. The company specializes in the discovery, development, and commercialization of targeted therapies and immunotherapies aimed at treating cancer and autoimmune diseases. Chi-Med has a robust pipeline, with several candidates in clinical development, including surufatinib, which has shown promise in treating neuroendocrine tumors. The company has established a significant presence in both the Chinese and global markets, leveraging its innovative drug development capabilities to meet the needs of healthcare providers and patients. Chi-Med is publicly traded on the Nasdaq and the London Stock Exchange, reflecting its commitment to transparency and investor engagement.

5. Enterome

• Website: enterome.com
• Ownership type: Venture Capital
• Headquarters: Paris, Île-De-France, France
• Employee distribution: France 100%
• Latest funding: $3.2M, October 2023
• Founded year: 2011
• Headcount: 51-200
• LinkedIn: enterome

Enterome is a biotechnology firm based in Paris, France, founded in 2011. The company specializes in cancer immunotherapy and drug discovery, focusing on developing innovative therapies that target various cancers. Enterome employs its proprietary OncoMimics™ approach, which leverages bacterial peptides to stimulate the immune system against tumors. Their pipeline includes ongoing clinical trials for treatments aimed at hematological malignancies and solid tumors, such as non-Hodgkin lymphoma and glioblastoma. Enterome has recently secured funding of approximately €3.18 million in October 2023, reflecting investor confidence in their research and development efforts. The company operates entirely within France and is dedicated to bringing new therapies to market through rigorous clinical trials and research initiatives.

6. NantKwest

• Website: nantkwest.com
• Ownership type: Corporate
• Headquarters: Culver City, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: December 2020
• Founded year: 2002
• Headcount: 51-200
• LinkedIn: nantkwest

NantKwest, now operating under the name ImmunityBio, is a biotechnology firm based in Culver City, California. Founded in 2002, the company is dedicated to developing innovative immunotherapies aimed at treating cancer and infectious diseases. Their primary product, ANKTIVA®, is a first-in-class immunotherapy that activates the immune system to combat tumor cells. ImmunityBio is actively involved in clinical trials, with a significant number of studies in Phase 2 and 3 development across various cancer types, including bladder cancer, glioblastoma, and non-small cell lung cancer. The company collaborates with institutions like the National Cancer Institute to explore new treatment avenues, demonstrating a commitment to addressing unmet medical needs. With a focus on enhancing the immune response rather than suppressing it, ImmunityBio aims to transform the treatment landscape for patients with serious diseases.

7. SOTIO Biotech

• Website: sotio.com
• Ownership type: Private Equity
• Headquarters: Prague, Prague, Czech Republic
• Employee distribution: Czech Republic 83%, United States (USA) 6%, Switzerland 6%, Other 5%
• Latest funding: $316.6M, December 2021
• Founded year: 2010
• Headcount: 201-500
• LinkedIn: sotio-a.s.

SOTIO Biotech, founded in 2010 and based in Prague, Czech Republic, is a biotechnology company dedicated to developing innovative cancer treatments. The firm specializes in clinical-stage research, focusing on immunotherapy solutions that aim to improve patient outcomes in oncology. SOTIO's product pipeline features advanced candidates such as IL-15 superagonists and antibody-drug conjugates, which are designed to enhance the immune response against various solid tumors. The company operates globally, with a significant presence in the Czech Republic, the United States, Switzerland, and China. SOTIO collaborates with leading healthcare providers and research institutions to drive its clinical trials and product development. In December 2021, SOTIO secured funding amounting to approximately $316 million, underscoring its potential and commitment to advancing cancer therapies.

8. TCRCure Biopharma Corp.

• Website: en.tcrcure.com
• Ownership type: Private
• Headquarters: Guangzhou, Guangdong, China
• Employee distribution: United States (USA) 67%, China 33%
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: tcrcure-biopharma-corp

TCRCure Biopharma Corp. is a biopharmaceutical company based in Guangzhou, China, with additional operations in the United States. Founded in 2016, TCRCure focuses on advancing cancer immunotherapy through the development of T cell therapies. The company operates research and development centers and manufacturing facilities in both the USA and China, ensuring compliance with current Good Manufacturing Practices (cGMP). TCRCure is dedicated to creating next-generation cancer treatments that aim to control tumor progression and convert cancers into manageable conditions. Their innovative platforms, such as ASPIRE and TRUST, enhance T cell recognition and improve the efficiency of drug development. TCRCure has initiated clinical trials for various cancers, including cervical and lung cancers, and has collaborated with prominent hospitals for translational research. Their pioneering work in TCR-T therapy, particularly for advanced recurrent solid tumors, marks a significant contribution to the field of immunotherapy.

9. Numab Therapeutics AG

• Website: numab.com
• Ownership type: Venture Capital
• Headquarters: Horgen, Zurich, Switzerland
• Employee distribution: Switzerland 100%
• Latest funding: Series C, $54.9M, January 2025
• Founded year: 2011
• Headcount: 51-200
• LinkedIn: numab-ag

Numab Therapeutics AG, based in Horgen, Zurich, Switzerland, is a biopharmaceutical company founded in 2011. The firm focuses on the development of multispecific biotherapeutics and immunology drugs, aiming to address significant unmet medical needs in patients, particularly in immunology and oncology. Numab employs proprietary technology platforms, including λ-Cap™ and MATCH™, to create innovative therapeutic solutions. Their pipeline includes advanced drug candidates, with a notable focus on NM26, a bispecific antibody targeting IL-4Rα and IL-31 for atopic dermatitis. The company has established partnerships with pharmaceutical firms, enhancing its development capabilities. Recently, Numab announced a significant acquisition by Johnson & Johnson, which underscores the value of its pipeline and technology. With a workforce of 51-200 employees and recent funding of approximately $54 million in a Series C round, Numab is positioned as an active and relevant entity in the biotech industry.

10. PROBIOMED S.A. de C.V.

• Website: probiomed.com.mx
• Ownership type: Corporate
• Headquarters: Mexico
• Employee distribution: Mexico 99%
• Latest funding: May 2022
• Founded year: 1970
• Headcount: 501-1000
• LinkedIn: probiomedmx

PROBIOMED S.A. de C.V. is a biopharmaceutical company based in Mexico, established in 1970. The company is dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products aimed at improving human health. With a workforce of approximately 657 employees, PROBIOMED focuses on providing access to high-tech therapies for serious diseases, including cancer, chronic kidney failure, rheumatoid arthritis, multiple sclerosis, and diabetes. Their product portfolio features a wide array of pharmaceutical solutions, including chemical generics and biocomparables such as monoclonal antibodies, fusion proteins, and recombinant vaccines. These products are designed to address autoimmune diseases, chronic degenerative disorders, hematological and metabolic disorders, as well as malignant neoplasms. PROBIOMED is committed to enhancing the quality of life for patients both in Mexico and globally, ensuring that effective treatments are accessible to those in need.

11. Elpiscience Biopharmaceuticals

• Website: elpiscience.com
• Ownership type: Private Equity
• Headquarters: Shanghai, Shanghai, China
• Employee distribution: China 100%
• Latest funding: Series C, $105.0M, May 2021
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: elpiscience-biopharmaceuticals-ltd

Elpiscience Biopharmaceuticals, founded in 2017 and based in Shanghai, China, is a clinical-stage biopharmaceutical company dedicated to developing innovative immuno-oncology therapies for cancer patients. The company focuses on targeting the tumor microenvironment to create effective cancer treatments. Elpiscience has established a robust pipeline that includes bispecific antibodies and other therapeutics aimed at addressing various oncology targets. Their approach leverages proprietary discovery platforms and extensive R&D capabilities, allowing them to advance their programs efficiently. Elpiscience has attracted significant investment, with a reported Series C funding round raising $105 million in May 2021. This funding supports their mission to discover and develop high-quality cancer therapeutics. The company collaborates with global biopharmaceutical firms and academic institutions to accelerate the development of their innovative therapies, demonstrating their active role in the industry.

12. Lyvgen Biopharma

• Website: lyvgen.com
• Ownership type: Venture Capital
• Headquarters: Shanghai, Shanghai, China
• Employee distribution: China 100%
• Latest funding: Series C, $10.0M, February 2021
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: lyvgen-biopharma

Lyvgen Biopharma, established in 2016 and based in Shanghai, China, is a biotechnology firm dedicated to the development of cancer immunotherapy. The company specializes in creating innovative antibody therapies aimed at enhancing the immune system's ability to combat tumors. Their research initiatives are centered around their proprietary xLinkMAb platform, which focuses on developing agonistic antibodies that can selectively activate immune responses in the tumor microenvironment. Lyvgen's clinical pipeline includes several promising candidates, such as LVGN6051, a CD137 (4-1BB) agonistic antibody, and LVGN7409, a CD40 agonistic antibody, both of which are undergoing clinical trials. The company has attracted significant venture capital, securing $10 million in Series C funding in February 2021, which underscores its potential and commitment to advancing cancer treatment options. Lyvgen Biopharma's primary customers include healthcare providers and patients seeking cutting-edge cancer therapies, positioning the company as a relevant player in the immunotherapy biotech sector.

13. Center of Molecular Immunology

• Website: cim.cu
• Ownership type: Private
• Headquarters: Havana, Havana, Cuba
• Employee distribution: Cuba 100%
• Founded year: 1994
• Headcount: 1001-5000
• LinkedIn: centrodeinmunolog%c3%adamolecular

The Center of Molecular Immunology (CIM), founded in 1994 and based in Havana, Cuba, is a private biotechnology company dedicated to the research, development, and production of therapeutic vaccines and biological products. With a workforce of over 500 employees, CIM focuses on innovative treatments for cancer and diseases affecting the immune system. Notably, the company has developed two therapeutic vaccines for advanced lung cancer: CIMAvax EGF and VAXIRA. These vaccines have been registered for use in patients with stage III and IV non-small cell lung cancer after initial chemotherapy, demonstrating a commitment to improving patient outcomes. CIM operates under Good Production Practices, ensuring the quality and safety of its products. Their work is not only significant for local patients but also positions them as a player in the global immunotherapy market, despite their limited international presence.

14. CatalYm GmbH

• Website: catalym.com
• Ownership type: Private Equity
• Headquarters: Planegg, Bavaria, Germany
• Employee distribution: Germany 100%
• Latest funding: Series D, $150.0M, July 2024
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: catalym

CatalYm GmbH, founded in 2016 and based in Planegg, Bavaria, Germany, is a biotechnology firm dedicated to advancing cancer immunotherapy. The company has identified GDF-15 as a significant mechanism of resistance in cancer therapy and is developing visugromab, a monoclonal antibody aimed at reversing this resistance. Their approach seeks to enhance anti-tumor immune responses, particularly in patients with solid tumors who have not responded to existing treatments. CatalYm is currently progressing through clinical trials, with a focus on combination therapies that include anti-PD-1 treatments. The company has recently secured $150 million in Series D funding to support its Phase 2b development program, underscoring its active role in the healthcare sector and its commitment to addressing unmet medical needs in cancer treatment.

15. Cugene Inc.

• Website: cugene.com
• Ownership type: Private
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: cugene

Cugene Inc., founded in 2016 and based in Waltham, Massachusetts, is a clinical-stage biotechnology company dedicated to advancing precision immunology and oncology medicines. The company specializes in developing innovative therapeutic solutions aimed at treating autoimmune diseases and cancer. Cugene employs precision molecular engineering to create novel molecules that selectively stimulate immune responses, promoting immune tolerance and enhancing treatment efficacy. Their pipeline includes therapies designed to reinvigorate exhausted T cells in tumors, ensuring targeted action that spares healthy cells. Cugene collaborates with healthcare providers and pharmaceutical firms to tackle pressing medical challenges, reflecting their commitment to improving patient outcomes through cutting-edge biomedicines.

16. Biond Biologics Ltd

• Website: biondbio.com
• Ownership type: Venture Capital
• Headquarters: Misgav, North, Israel
• Employee distribution: Israel 100%
• Latest funding: Series C, $15.0M, November 2021
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: biond-biologics-ltd

Biond Biologics Ltd, founded in 2016 and based in Misgav, Israel, is a biotechnology company dedicated to developing innovative therapies for cancer treatment. The company specializes in creating biological products and drug delivery platforms that specifically target immune evasion mechanisms. Biond's research is grounded in real-world patient and tumor samples, allowing them to develop therapies that address significant challenges in cancer treatment. Their pipeline includes several candidates in immuno-oncology, such as BND-22, a novel immune checkpoint inhibitor currently in phase 1 clinical trials, and BND-35, which is expected to enter phase 1 trials in early 2024. Biond has also developed the INspire platform, a transformative intracellular delivery system for biologics, enhancing the potential to target previously considered 'undruggable' intracellular targets. The company has received $15 million in funding as of November 2021, reflecting confidence in their innovative approach and potential impact in the oncology space.

17. Tizona Therapeutics, Inc.

• Website: tizonatx.com
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $300.0M, July 2020
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: tizona-therapeutics

Tizona Therapeutics, Inc., founded in 2015 and based in South San Francisco, California, is a biotechnology firm dedicated to advancing immunotherapy solutions for cancer. The company is focused on translating novel scientific insights into first-in-class treatments, with a particular emphasis on their lead product, TTX-080. This innovative therapy targets immune evasion strategies employed by tumors, aiming to restore the body's natural immune response against cancer. Tizona's commitment to research and development is underscored by their active clinical trials, including a Phase 1b study evaluating TTX-080 in combination with other therapies for advanced cancers. The company has attracted significant venture capital funding, totaling $300 million as of July 2020, which reflects strong investor interest in their mission to enhance treatment outcomes for cancer patients. Tizona Therapeutics operates within the pharmaceutical and biotechnology sectors, with a clear focus on life sciences and oncology.

18. CDR-Life Inc.

• Website: cdr-life.com
• Ownership type: Private Equity
• Headquarters: Horgen, Zurich, Switzerland
• Employee distribution: Switzerland 100%
• Latest funding: Series A, $76.0M, April 2022
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: cdr-life-inc.

CDR-Life Inc., founded in 2017 and based in Horgen, Zurich, Switzerland, is a biotechnology firm dedicated to advancing immunotherapy solutions for cancer. The company specializes in developing targeted T cell engagers (TCEs) aimed at eliminating hard-to-treat solid tumors. Their proprietary M-gager® platform allows for the targeting of a wide range of cancer antigens, facilitating the creation of potent and selective TCE therapeutics. CDR-Life collaborates with healthcare providers and pharmaceutical companies to bring their innovative therapies to market. The company has recently secured $76 million in Series A funding, which underscores its potential and commitment to developing next-generation immunotherapies. With a team of experienced drug developers and a robust pipeline, CDR-Life is positioned to make significant contributions to the field of cancer treatment.

19. ImmuneOncia Therapeutics Inc.

• Website: immuneoncia.com
• Ownership type: Venture Capital
• Headquarters: Gangseo-Gu, Seoul, South Korea
• Employee distribution: South Korea 100%
• Latest funding: $20.6M, January 2022
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: immuneoncia

ImmuneOncia Therapeutics Inc. is a biopharmaceutical company based in Gangseo-Gu, Seoul, South Korea, specializing in immuno-oncology. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, ImmuneOncia aims to develop innovative immunotherapies to combat cancer. The company is focused on creating monoclonal antibodies that target immune checkpoints, which play a crucial role in regulating the immune response to tumors. Their pipeline includes IMC-001, an anti-PD-L1 monoclonal antibody currently in a multi-regional Phase II study in Korea and China, and IMC-002, an anti-CD47 monoclonal antibody that has recently initiated a Phase I study in the U.S. ImmuneOncia's commitment to advancing cancer treatment is underscored by their recent funding of approximately $20.6 million in January 2022, which supports their ongoing research and development efforts.

20. PsiOxus

• Website: psioxus.com
• Ownership type: Private Equity
• Headquarters: Abingdon, England, United Kingdom (UK)
• Latest funding: $31.8M, May 2015
• Founded year: 2010
• Headcount: 51-200
• LinkedIn: psioxus

PsiOxus, also known as Akamis Bio, is a clinical-stage biotechnology company based in Abingdon, England. Founded in 2010, the company specializes in tumor gene therapy, focusing on the development of Tumor-Specific Immuno-Gene (T-SIGn®) therapeutics. These innovative treatments are designed to enhance the immune system's ability to recognize and attack solid tumors. PsiOxus has a growing pipeline of T-SIGn® therapeutics, with their lead program, NG-350A, currently in Phase 1b clinical trials. The company has treated over 200 patients, demonstrating a consistent safety profile and promising preliminary clinical activity. PsiOxus has also secured funding, with a reported amount of $31.75 million in 2015, which supports their ongoing research and development efforts in the oncology sector.

21. Prokarium

• Website: prokarium.com
• Ownership type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 100%
• Latest funding: Series B, $30.0M, February 2023
• Founded year: 2012
• Headcount: 11-50
• LinkedIn: prokarium

Prokarium is a biopharmaceutical company based in London, UK, founded in 2012. The company specializes in developing innovative cancer treatments, particularly through microbial immunotherapy. Prokarium's foundational technology utilizes a proprietary strain of bacteria, known as ZH9, to target tumors and stimulate strong anti-tumor immunity. Their research focuses on addressing significant unmet medical needs in cancer care, with a particular emphasis on bladder cancer. Prokarium's pipeline includes programs aimed at transforming treatment paradigms and restoring immune responses in patients who are currently underserved by existing therapies. In February 2023, Prokarium secured $30 million in Series B funding to advance their lead program into clinical trials and further develop their novel therapeutic platforms. This funding reflects their ongoing commitment to improving patient outcomes through innovative approaches in cancer treatment.

22. Hemispherx Biopharma, Inc.

• Website: hemispherx.net
• Ownership type: Private
• Headquarters: Ocala, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $1.0M, February 2017
• Founded year: 1966
• Headcount: 11-50
• LinkedIn: hemispherx-biopharma-inc.

Hemispherx Biopharma, Inc., also known as AIM ImmunoTech, is a biotechnology firm based in Ocala, Florida. Founded in 1966, the company is dedicated to developing immunology solutions targeting a range of diseases, particularly cancer and viral infections. Their flagship product, Ampligen® (rintatolimod), is an immuno-modulator that has demonstrated broad-spectrum activity in preclinical and clinical studies. Currently, Ampligen® is being evaluated in various clinical trials, including those for pancreatic cancer and chronic fatigue syndrome. The company has also received funding, with a reported amount of $1 million in 2017, which supports its ongoing research and development efforts. AIM ImmunoTech is focused on providing innovative therapeutic options for patients and healthcare providers, emphasizing their commitment to advancing treatment in the immunotherapy space.

23. Cartography Biosciences

• Website: cartography.bio
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $57.0M, July 2022
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: cartographybio

Cartography Biosciences, founded in 2020 and based in South San Francisco, California, is a biotechnology firm dedicated to the development of cancer immunotherapies. The company aims to identify precise targets for cancer treatment, leveraging cutting-edge technologies to improve the effectiveness and safety of therapies. Their innovative approach includes creating a comprehensive antigen atlas that analyzes cancers based on antigen expression, which could significantly enhance the precision of immunotherapies. Cartography has attracted substantial investment, securing $57 million in Series A funding in July 2022. Their collaborations, such as the recent partnership with Gilead to develop oncology therapies, further underscore their active role in the industry and commitment to advancing cancer treatment.

24. NeoTX Therapeutics LTD

• Website: neotx.com
• Ownership type: Private
• Headquarters: Rehovot, Center, Israel
• Employee distribution: Israel 80%, United States (USA) 20%
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: neotx-therapeutics-ltd

NeoTX Therapeutics LTD, based in Rehovot, Israel, is a private biotechnology firm founded in 2015. The company specializes in developing innovative cancer therapeutics, with a strong emphasis on immunotherapy. Their flagship product, Naptumomab estafenatox (NAP), is designed to target advanced solid tumors and is currently undergoing clinical trials. NeoTX's approach utilizes a unique Tumor Targeted Superantigen (TTS) technology, which aims to enhance the immune system's ability to recognize and attack cancer cells. This technology has the potential to improve the effectiveness of existing treatments, including checkpoint inhibitors and chemotherapy. The company collaborates with healthcare providers and is actively engaged in clinical research to bring its therapies to market, demonstrating a commitment to addressing significant unmet needs in cancer treatment.

25. Trishula Therapeutics, Inc.

• Website: trishulatx.com
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: August 2020
• Founded year: 2020
• Headcount: 1-10
• LinkedIn: trishulatx

Trishula Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2020. The company is dedicated to developing innovative cancer therapies, with a particular emphasis on TTX-030, a first-in-class anti-CD39 antibody. This antibody is designed to target the mechanisms of immune evasion within the tumor microenvironment, aiming to enhance the immune system's ability to combat cancer. Trishula is currently conducting clinical trials, including a randomized Phase 2 study for TTX-030 in frontline metastatic pancreatic cancer. The company collaborates with other organizations to further its research and development efforts, focusing on improving outcomes for patients with advanced cancers.

26. EvolveImmune Therapeutics

• Website: evolveimmune.com
• Ownership type: Venture Capital
• Headquarters: Branford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $20.0M, October 2024
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: evolveimmune-therapeutics

EvolveImmune Therapeutics, founded in 2020 and based in Branford, Connecticut, is a biotechnology firm dedicated to the development of precision cancer medicines. The company specializes in creating innovative immunobiologics and T cell engagers aimed at enhancing anti-cancer immunity. Their research is centered on overcoming CD8 T cell exhaustion within the tumor microenvironment, which is crucial for effective cancer treatment. EvolveImmune's pipeline includes several promising programs, such as EVOLVE-104 and EVOLVE-105, targeting various solid tumors and B cell malignancies. The company has recently raised $37 million in funding, which includes strategic investments from notable partners like Bristol Myers Squibb. This financial backing supports their ongoing research and development efforts, positioning them as a relevant player in the immunotherapy sector.

Immunotherapy Biotech Insights: Key Companies

Want to Find More Immunotherapy Biotech Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!